SB-277,011A is a drug which acts as a potent and selective dopamine D3 receptor antagonist,[1] which is around 80–100 times selective for D3 over D2,[2] and lacks any partial agonist activity.

[3] SB-277,011A is used in the study of addiction to stimulant drugs such as nicotine[4] and cocaine.

[5][6] Where cocaine reduces the threshold for brain electrical self-stimulation in rats, an indication of cocaine's rewarding effects, SB-277,011A completely reverses this effect.

[11][12][13] Another potential application for SB-277,011A is in the treatment of schizophrenia,[14] and it may be particularly useful in treating comorbid patients who are both schizophrenic and addicted to drugs.

[15] However it may worsen side effects such as tardive dyskinesia in patients who are already prescribed antipsychotic drugs.